Every Form 4 that Revolution Medicines, Inc. Warrant (RVMDW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RVMDW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVMDW filings page.
Revolution Medicines, Inc. reported that General Counsel Jeff Cislini received equity awards. He was granted a stock option for 32,500 shares at an exercise price of $0.00 and an award of 14,500 shares of common stock. The option vests in equal monthly installments over four years starting on March 1, 2026, becoming fully vested on the fourth anniversary, subject to his continued service.
Revolution Medicines, Inc. reported that Chief Financial Officer Anders Jack acquired new equity awards. On March 1, 2026, he received a stock option covering 45,400 shares at an exercise price of $0.00 per share and a grant of 20,200 shares of common stock, both recorded as direct ownership.
The filing states that shares held include 62,538 restricted stock units. The option vests in equal monthly installments over 48 months starting March 1, 2026, so that all 45,400 option shares are fully vested and exercisable by the fourth anniversary, contingent on his continued service.
Revolution Medicines’ general counsel, Jeff Cislini, reported a small, pre-planned stock sale. On January 21, 2026, he sold 908 shares of Revolution Medicines common stock at $115.60 per share under a Rule 10b5-1 trading plan adopted on March 13, 2025. After this sale, he beneficially owned 46,976 shares, which include 38,769 restricted stock units that typically vest over time.